Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 2/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803444 | 1.00 | MEN1 (0.47) | MEN1KMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL6807744 | 0.90 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL6807740 | 0.90 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL6827938 | 0.90 | ITGA4 (0.46) | MEN1KMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL6827943 | 0.90 | ITGA4 (0.46) | MEN1KMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL6808095 | 0.85 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL6808091 | 0.85 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2NPC1TP53 | |
| SCHEMBL6796461 | 0.80 | PTPRB (0.53) | — | |
| SCHEMBL6796473 | 0.80 | PTPRB (0.53) | — | |
| SCHEMBL6799985 | 0.80 | ITGA4 (0.51) | MEN1KMT2ASMN1; SMN2NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | MEN1 4379/4885KMT2A 2262/4885SMN1; SMN2 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.